cetrorelix and 19-nortestosterone-4-hexoxyphenylpropionate

For male hormonal contraception, combined administration of gonadotrophin-releasing hormone (GnRH) antagonists and androgens effectively suppresses spermatogenesis to azoospermia. In non-human primates this suppression can be maintained more easily by androgens alone.. A clinical trial with six healthy volunteers was performed to test this approach in man. Loading doses of 10 mg/day of the GnRH antagonist cetrorelix were given subcutaneously for 5 days, followed by maintenance doses of 2 mg/day up to week 12. At 2 weeks after the first GnRH antagonist injection, androgen substitution was initiated with a loading dose of 400 mg 19-nortestosterone hexyloxyphenylpropionate (19NT-HPP) intramuscularly, followed by injections of 200 mg 19NT-HPP every 3 weeks up to week 26.. Serum concentrations of LH, FSH and testosterone were effectively suppressed by cetrorelix administration. Within 12 weeks, azoospermia was achieved in all six volunteers. After cessation of cetrorelix injections in week 12, gonadotrophins and testosterone increased significantly despite continued 19NT-HPP injections. In parallel, spermatogenesis was restimulated in five of six volunteers.. Combined administration of cetrorelix and 19NT-HPP leads to azoospermia within 3 months. However, complete azoospermia cannot be maintained by continued injections of the non-aromatizable 19NT-HPP alone.

Topics: Adolescent; Adult; Anabolic Agents; Contraceptive Agents, Male; Ejaculation; Estradiol; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hemoglobins; Humans; Inhibins; Injections, Intramuscular; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Nandrolone; Oligospermia; Prolactin; Prostate; Sex Hormone-Binding Globulin; Sexual Behavior; Sperm Count; Sperm Motility; Spermatogenesis; Testis; Testosterone